Company

Board of Directors

Our Board of Directors is comprised of key investors who provide leadership through corporate governance and strategic support of our vision and overall strategy.

BRADLEY
WERTZ

Mr. Wertz is the Executive Chairman of GenomOncology. Formerly the President and COO of Rosetta, he helped grow the company from slightly less than $115M to $225M before it’s sale to Publicis. Before Rosetta, He served as COO for Brulant which grew from $17M to $75M in three years, culminating in the sale of Brulant to Rosetta. Brad has also held senior executive positions at several other startups including bioinformatics company Acero.

LEE
ZAPIS

Mr. Zapis is the President of Zapis Capital Group, a closely held corporation that makes equity investments in people with passion and expertise to lead their business to success. Lee is a hands-on investor and currently sits on the boards of GenomOncology, YouBeauty.com and Listener Driven Radio - companies that he personally, or his firm has invested in.

BRIAN
LADEN, PH.D.

Dr. Laden co-founded TriStar Technology Ventures in 2009, and serves on the Board of Directors for Molecular Sensing and the Advisory Board for Cumberland Emerging Technologies. He also holds an observer seat on the Boards of TVA, BioStable and GenomOncology. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University.

JONATHAN
SEATON

Mr. Seaton, most recently the Senior Vice President of Corporate and Business Development / Government Affairs at Illumina, has extensive industry experience. He previously held leadership roles at F. Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks. Jonathan studied medicine at the University of Manchester, and has a BSc degree in Molecular Biology and Biochemistry from the University of Durham, and an MBA from the Saïd Business School at the University of Oxford.

MANUEL J.
GLYNIAS

Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Prior to GenomOncology, Manuel was a partner at Rosetta where he helped develop big data solutions for e-commerce clients, and was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics. He also developed a number of commercial software platforms including MacGene, Gene Works, and Primer Express.
  • BRADLEY
    WERTZ


    Mr. Wertz is the Executive Chairman of GenomOncology. Formerly the President and COO of Rosetta, he helped grow the company from slightly less than $115M to $225M before it’s sale to Publicis. Before Rosetta, He served as COO for Brulant which grew from $17M to $75M in three years, culminating in the sale of Brulant to Rosetta. Brad has also held senior executive positions at several other startups including bioinformatics company Acero.

  • LEE
    ZAPIS


    Mr. Zapis is the President of Zapis Capital Group, a closely held corporation that makes equity investments in people with passion and expertise to lead their business to success. Lee is a hands-on investor and currently sits on the boards of GenomOncology, YouBeauty.com and Listener Driven Radio - companies that he personally, or his firm has invested in.

  • BRIAN
    LADEN, PH.D.


    Dr. Laden co-founded TriStar Technology Ventures in 2009, and serves on the Board of Directors for Molecular Sensing and the Advisory Board for Cumberland Emerging Technologies. He also holds an observer seat on the Boards of TVA, BioStable and GenomOncology. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University.

  • JONATHAN
    SEATON


    Mr. Seaton, most recently the Senior Vice President of Corporate and Business Development / Government Affairs at Illumina, has extensive industry experience. He previously held leadership roles at F. Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks. Jonathan studied medicine at the University of Manchester, and has a BSc degree in Molecular Biology and Biochemistry from the University of Durham, and an MBA from the Saïd Business School at the University of Oxford.

  • MANUEL J.
    GLYNIAS


    Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Prior to GenomOncology, Manuel was a partner at Rosetta where he helped develop big data solutions for e-commerce clients, and was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics. He also developed a number of commercial software platforms including MacGene, Gene Works, and Primer Express.

Schedule a demo